GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MPX International Corp (FRA:2J6) » Definitions » Research & Development

MPX International (FRA:2J6) Research & Development : €0.00 Mil (TTM As of Mar. 2022)


View and export this data going back to 2019. Start your Free Trial

What is MPX International Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. MPX International's Research & Development for the three months ended in Mar. 2022 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2022 was €0.00 Mil.

MPX International Research & Development Historical Data

The historical data trend for MPX International's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MPX International Research & Development Chart

MPX International Annual Data
Trend Sep18 Sep19 Sep20 Sep21
Research & Development
- - - -

MPX International Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MPX International Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MPX International  (FRA:2J6) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MPX International Research & Development Related Terms

Thank you for viewing the detailed overview of MPX International's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

MPX International (FRA:2J6) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MPX International Corp (FRA:2J6) » Definitions » Research & Development
Comparable Companies
XCNQ:CBDN TSXV:NU XCNQ:PBIC XCNQ:FUZN XCNQ:GHG XCNQ:LUV XCNQ:AMS.X TSXV:CANB XCNQ:NLV XCNQ:BCBC XTER:MRK ZTS TSE:4502 NSE:SUNPHARMA CTLT TSE:4507 SHSE:600196 SZSE:000538 VTRS NSE:DIVISLAB
Traded in Other Exchanges
N/A
Address
5255 Yonge Street, Suite 701, Toronto, ON, CAN, M2N 6P4
Website
https://www.mpxinternationalcorp.com
MPX International Corp is a diversified cannabis company focused on developing and operating assets across the global medical and adult use and engaged in cultivating, manufacturing and marketing products that include cannabinoids as their primary active ingredient. The firm is organized into three segments: Canada, Europe/Africa, and Asia-Pacific. The Canada operating segment's principal business activities consist of production and sale of cannabis, video learning and engagement, patient counselling and referral services. The Europe/Africa operating segment's consist of the production and sale of cannabis and hemp-related products. The Asia-Pacific consist of the production and sale of cannabis. The majority of the revenue is generated in Canada.

MPX International (FRA:2J6) Headlines

No Headlines